Pharmaceutical Medical Coding: Insights into Its Role in Clinical Trial Processes | Chapter 16 | Medical Science: Trends and Innovations Vol. 13

In the context of clinical trials, the meticulous collection and management of data are fundamental to the success and reliability of the research outcomes. The increasing complexity of medical terminology in clinical trials necessitates the use of standardised medical coding systems to ensure uniformity in data interpretation. This data collection process is primarily conducted through Case Record Forms (CRFs) for paper-based studies and electronic Case Record Forms (eCRFs) for digital or web-based trials. These data collection instruments are meticulously designed to capture a wide range of relevant information that is crucial for evaluating the safety and efficacy of clinical interventions. Key elements documented in these forms include Adverse Events (AEs), Medical History (MH), and Concomitant Medications (CM) that participants may be taking concurrently with the study medication. This article provides an overview of the processes involved in medical coding within clinical data management, specifically highlighting the role of established medical dictionaries like the Medical Dictionary for Regulatory Activities (MedDRA) and the World Health Organisation Drug Dictionary Enhanced (WHO-DDE). In the medical coding workflow, the precoding process involves a series of important steps to ensure that the relevant medical coding dictionaries are correctly integrated into the coding tool used for clinical trials. These dictionaries aid in categorising medical terms from reports generated throughout the lifecycle of clinical trials, addressing challenges such as variations in data presentation due to diverse investigator backgrounds.  Medical coding typically involves a precoding process, followed by auto-coding where terms matching those in the dictionary are automatically assigned codes. However, discrepancies may arise, necessitating manual coding to address unclear or ambiguous terms. The medical coding team plays a critical role in ensuring accurate coding by collaborating with investigators to clarify ambiguous terms and rectify errors in data recorded on Case Report Forms (CRFs). The MedDRA structure includes multiple hierarchical levels from Low Level Terms (LLTs) to System Organ Classes (SOCs), providing a comprehensive framework for handling diverse medical terms. Common issues faced by coders, including illegible terms, abbreviations, and improper categorisation, are also discussed. By understanding these processes and challenges, medical coders can enhance the reliability of clinical trial data, ultimately contributing to safer and more effective therapeutic outcomes. In conclusion, accurately managing and reducing errors in medical coding and billing is crucial for the accuracy and financial health of an organisation. To minimise these errors, it’s essential to provide thorough training on coding standards, conduct regular audits and monitoring, and enhance knowledge in areas such as medical terminology, anatomy and physiology, medical abbreviations, and diagnoses. While coding and billing mistakes can be avoided, understanding their root causes is key to effectively reducing and managing them.

 

 

Author (s) Details

Shubham Kamble
The Royal Gondwana College of Pharmacy, Nagpur, India.

Janhavi Indurkar
Central India College of Pharmacy, Nagpur, India.

 

Akshay Ramteke
Central India College of Pharmacy, Nagpur, India.

 

Smita Meshram
Central India College of Pharmacy, Nagpur, India.

 

Please see the book here:- https://doi.org/10.9734/bpi/msti/v13/5312

A Review on the Clinical Application for Tissue Engineered Vascular Grafts | Chapter 2 | Achievements and Challenges of Medicine and Medical Science Vol. 3

Cardiovascular-related medical conditions remain a significant cause of death worldwide despite the advent of tissue engineering research more than half a century ago. There is a continued and growing demand for vascular conduits for reconstructing or bypassing vascular occlusion and aneurysms. Although autologous tissue is still the preferred treatment, donor tissue is limited, and there remains a need for tissue engineered vascular grafts (TEVGs). The production of particularly large vascular tissue (> 1 cm³) in vitro meets the clinical needs of tissue grafts and biological research applications. The use of TEVGs in human patients remains limited due to issues related to thrombogenesis and stenosis. In addition to the advancement of simple manufacturing methods, the shift of attention to the combination of synthetic polymers and bio-derived materials and cell sources has enabled synergistic combinations of vascular tissue development. The aim of the study was to propose potential solutions and prospects in this highly dynamic field of research. This review detailed the selection of biomaterials and cell sources and related clinical trials in developing large diameter vascular grafts that can be applied clinically. Finally, the remaining challenges in the tissue engineering field which can be seen from complex requirements by covering both basic and clinical research from the perspective of material design, have been discussed. The study concludes that while autologous tissue has been successfully used to treat many cardiovascular diseases (e.g., atherosclerosis), autologous vascular tissue for transplantation is often insufficient. Therefore, the development of TEVGs offers a promising alternative. Advances in TEVG manufacturing technologies could potentially address these limitations in the near future. Additionally, the ability to 3D print vascular grafts with satisfactory properties is now a reality, offering new possibilities for treatment.

 

Author (s) Details

 

Tatsuya Watanabe
Center for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USA.

 

Satoshi Yuhara
Center for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USA.

 

Junya Matsuda
Center for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USA.

 

Toshiharu Shinoka
Center for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USA, Department of Cardiothoracic Surgery, Nationwide Children’s Hospital, Columbus, OH 43205, USA and Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

 

Please see the book here:- https://doi.org/10.9734/bpi/acmms/v3/2691

Drug Discovery in Pharmaceutical Chemistry: An In-Depth Exploration | Chapter 8 | Pharmaceutical Research - Recent Advances and Trends Vol. 3

Drug discovery in pharmaceutical chemistry is a complex, multi-stage process aimed at identifying new compounds that can become effective therapeutic agents. This process involves several key phases: target identification and validation, hit identification, hit-to-lead development, lead optimization, preclinical development, and clinical development, culminating in regulatory approval. Each stage integrates diverse scientific disciplines and advanced technologies to ensure the discovery of viable drug candidates. Challenges such as high failure rates, complex disease biology, safety and toxicity concerns, and significant time and cost investments are inherent to this process. However, emerging trends like artificial intelligence, machine learning, personalized medicine, and the development of biologics and biosimilars are revolutionizing drug discovery, enhancing efficiency, and paving the way for more targeted and effective treatments. This exploration provides a detailed overview of each stage, highlights the associated challenges, and discusses the innovative trends that are shaping the future of pharmaceutical research.

 

Author (s) Details

Shivkant Patel
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At and Po. Piparia, Ta. Waghodia, 391760, Vadodara, Gujarat, India.

 

Dillip Kumar Dash
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At and Po. Piparia, Ta. Waghodia, 391760, Vadodara, Gujarat, India.

 

Dipti Gohil
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At and Po. Piparia, Ta. Waghodia, 391760, Vadodara, Gujarat, India.

Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At and Po. Piparia, Ta. Waghodia, 391760, Vadodara, Gujarat, India.

 

Dhanya B. Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At and Po. Piparia, Ta. Waghodia, 391760, Vadodara, Gujarat, India.

 

Please see the book here:- https://doi.org/10.9734/bpi/prrat/v3/981

Real World Evidence: Unlocking New Insights in Drug Safety | Chapter 1 | Recent Updates in Disease and Health Research Vol. 1

Real-world evidence (RWE) is revolutionizing drug safety assessment by drawing insights from diverse data sources that represent real-world clinical practice, healthcare systems, and patient experiences. This paradigm shift challenges the limitations of traditional clinical trials, which occur in controlled environments and may not capture rare adverse events or real-world complexities. RWE harnesses extensive data from sources like electronic health records, claims data, patient registries, social media, and wearable devices, allowing a more authentic perspective on drug safety. The scale and duration of data collection in RWE facilitate the detection of rare adverse events and trends that might be missed in clinical trials. Furthermore, the integration of RWE into drug safety assessment relies on big data and advanced analytics, including machine learning and artificial intelligence. These technologies process vast datasets, identify associations, predict adverse events, and enable real-time monitoring, enhancing drug safety evaluation. In pharmacovigilance and post-market surveillance, RWE complements data from clinical trials, providing comprehensive insights into long-term drug safety and facilitating more efficient adverse event reporting. In the era of precision medicine, RWE helps identify subpopulations vulnerable to adverse events or benefiting more from specific drugs, tailoring treatments to individual patients. However, the use of RWE raises ethical and regulatory challenges related to data privacy, consent, data quality, and bias, necessitating a balance between innovation and patient safety. As RWE continues to expand, it promises to redefine drug safety assessment, benefiting patients, healthcare providers, researchers, and the pharmaceutical industry. Harnessing the potential of RWE is crucial to ensure the development of safe and effective pharmaceuticals in modern healthcare.

Author(s) Details:

Rajesh Hadia,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Rahul Trivedi,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Cyril Sajan,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Varunsingh Saggu,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Sunil Baile,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Sunil Kardani,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Hemraj Singh Rajput,
Department of Pharmacy, Sumandeep Vidyapeeth (Deemed to be University), Vadodara-391760, Gujarat, India.

Please see the link here: https://stm.bookpi.org/RUDHR-V1/article/view/13209

A Systematic Review and Meta-Analysis of Randomized Clinical Trials on the Benefits of Exercise in Heart Failure Patients | Chapter 9 | Current Progress in Medicine and Medical Research Vol. 1

Objective: To refurbish Sagar et al. orderly review and meta-analysis on exercise-based restoration in heart failure.Methods: MEDLINE, OVID and cross citations were searched for randomized dispassionate trials published 'tween February 2013 to August 2018 on exercised-located cardiac rehabilitation. Trials accompanying at least 6 months follow up were contained if with exercise preparation program alone or as a component of inclusive cardiac rehabilitation program compared accompanying groups without exercise formula.Results: A total of 43 randomized clinical troubles involving 11,989 patients mainly with weakened EF and NYHA class ll-lll were included in the study. Exercise training program formula in heart failure subjects was shown to decreased the all-cause mortality (RR=0.76; 95%CI= 0.66, 0.87; P= 0.001), all cause hospitalization later 12 months (RR=0.70; 95% CI= 0.52, 0.96; P= 0.02) rehospitalization due to heart attack (RR= 0.49; 95% CI= 0.44, 0.55; P= <0.0001) and improvement in status-of-life scores (RR= -0.36; 95% CI= -0.58, -0.14; P= 0.002).  All-cause mortality and  therapy admission following in position or time 12 months follow up granted significant benefits with exercise medicine program, particularly on exercise background(p=0.026) and exercise dose (p=0.013), individually, as revealed by the univariate meta-reversion results.Conclusion: Exercise therapy either in center or home located has  been proved to benefit heart failure patients in lowering the risk of all-cause mortality until 12 months, hospital admittance up 12 months, and gave better quality of history. The new studies included have further heartened the findings of former studies that an exercise therapy program provides benefit to heart attack patients, either as an “unique” intervention or in addition to a cardiac rehabilitation program; and that the background and dose of an exercise cure program provide important impact in reducing the risk of all-cause mortality and treatment after 12 months make inquiries, respectively.

Author(s) Details:

F. Cabahug, Reagan,

Metro Davao and Research Center, Davao City, Philippines.

Gina Montalan,
Ateneo de Davao University, Graduate School, Davao City, Philippines.

Irma P. Yape,
St Luke’s Medical Center, Quezon City, Philippines.

Maria Christina Micosa,
Metro Davao and Research Center, Davao City, Philippines.

Please see the link here: https://stm.bookpi.org/CPMMR-V1/article/view/11227

Understanding the Basics of Research as a Beginner: A Highlighter | Chapter 7 | Current Innovations in Medicine and Medical Science Vol. 3

 Health exploration is conducted for theoretical purposes and when we've some good substantiation or effective outgrowth also we go for applied exploration. There are also forestallment and remedial angles to doing health exploration as well, in the sense some of the preventative technologies as they crop , they must be tested out through exploration styles before available. Research has advanced by hops and bounds; scientific advancement is completely dependent on curiousness and inexhaustible cooperation collaboration. The word exploration is so charming to a neophyte that the pupil fraternity is overwhelmed by this exertion. Anyhow of the field, exploration is now an essential element of the educational system. There are other languages which are also employed;i.e perpetration exploration and Translational Research. numerous of the government programs get enforced and what's important to understand at this particular point of time is how these programs are performing well and it's also thus important to makemid-course corrections, if they're necessary or to decide in which areas you need specific angles of the programs to be strengthened and so on. This composition is intended to raise introductory mindfulness about exploration and its factors, particularly among exploration- acquainted scholars studying medical, paramedical, confederated health lores, and so on.

Author(s) Details:

M. V. Ravishankar,
Department of Anatomy JSS Medical College JSS Academy of Higher Education & Research, Mysuru, India.

C. S. Vidya,
Department of Anatomy JSS Medical College JSS Academy of Higher Education & Research, Mysuru, India.

Please see the link here: https://stm.bookpi.org/CIMMS-V3/article/view/8381